Recent blog posts
JAML Biologics Sequence Review Report 2026: Junctional adhesion molecule-like Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
JAML Biologics Sequence Review Report 2026: Junctional adhesion molecule-like Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of JAML sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
JAM3 Biologics Sequence Review Report 2026: Junctional adhesion molecule C Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
JAM3 Biologics Sequence Review Report 2026: Junctional adhesion molecule C Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of JAM3 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
JAM2 Biologics Sequence Review Report 2026: Junctional adhesion molecule B Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
JAM2 Biologics Sequence Review Report 2026: Junctional adhesion molecule B Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of JAM2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
ITGB1BP2 Biologics Sequence Review Report 2026: Integrin beta-1-binding protein 2 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
ITGB1BP2 Biologics Sequence Review Report 2026: Integrin beta-1-binding protein 2 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of ITGB1BP2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
ITGA11 Biologics Sequence Review Report 2026: Integrin alpha-11 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
ITGA11 Biologics Sequence Review Report 2026: Integrin alpha-11 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of ITGA11 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
INSRR Biologics Sequence Review Report 2026: Insulin receptor-related protein Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
INSRR Biologics Sequence Review Report 2026: Insulin receptor-related protein Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of INSRR sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
IGFL4 Biologics Sequence Review Report 2026: Insulin growth factor-like family member 4 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
IGFL4 Biologics Sequence Review Report 2026: Insulin growth factor-like family member 4 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of IGFL4 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
IGFL3 Biologics Sequence Review Report 2026: Insulin growth factor-like family member 3 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
IGFL3 Biologics Sequence Review Report 2026: Insulin growth factor-like family member 3 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of IGFL3 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
IGFL2 Biologics Sequence Review Report 2026: Insulin growth factor-like family member 2 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
IGFL2 Biologics Sequence Review Report 2026: Insulin growth factor-like family member 2 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of IGFL2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
IGFL1 Biologics Sequence Review Report 2026: Insulin growth factor-like family member 1 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
IGFL1 Biologics Sequence Review Report 2026: Insulin growth factor-like family member 1 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of IGFL1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
IGFBPL1 Biologics Sequence Review Report 2026: Insulin-like growth factor-binding protein-like 1 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
IGFBPL1 Biologics Sequence Review Report 2026: Insulin-like growth factor-binding protein-like 1 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of IGFBPL1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
IGFBP7 Biologics Sequence Review Report 2026: Insulin-like growth factor-binding protein 7 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
IGFBP7 Biologics Sequence Review Report 2026: Insulin-like growth factor-binding protein 7 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of IGFBP7 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →